Evidence map›Paper›PMID 28844114›Full record

ReviewVirchows Archiv : an international journal of pathology2017

The clinicopathologic spectrum of mature aggressive B cell lymphomas.

Lisa Rimsza, Stefania Pittaluga, Stephan Dirnhofer, Christiane Copie-Bergman, Laurence de Leval, Fabio Facchetti, Stefano Pileri, Andreas Rosenwald, Andrew Wotherspoon, Falko Fend

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. High-grade B-cell lymphoma with 11q aberrations: A single-center study.Journal of clinical and experimental hematopathology : JCEH · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 9 institutions in 6 countries.

Lisa RimszaDepartment of Laboratory Medicine and Pathology, The Mayo Clinic, 13400 E. Shea Boulevard, Collaborative Research Building, 1-265, Scottsdale, AZ, 85259, USA. Rimsza.Lisa@mayo.edu.
Stefania PittalugaLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Stephan DirnhoferInstitute of Pathology and Genetics, University Hospital Basel, University of Basel, Basel, Switzerland.
Christiane Copie-BergmanDepartment of Pathology, Hospital Henri Mondor, INSERM U955, Universite Paris Est, Creteil, France.
Laurence de LevalInstitute of Pathology, University Hospital Lausanne, Lausanne, Switzerland.
Fabio FacchettiSection of Pathology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Stefano PileriUnit of Hematopathology, European Institute of Oncology, Milan, Italy.
Andreas RosenwaldInstitute of Pathology, University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Andrew WotherspoonDepartment of Histopathology, Royal Marsden Hospital, Sutton, UK.
Falko FendInstitute of Pathology and Neuropathology and Comprehensive Cancer Center, University Hospital Tübingen, Liebermeisterstrasse 8, 72076, Tübingen, Germany. falko.fend@med.uni-tuebingen.de.ORCID http://orcid.org/0000-0002-5496-293X
European Institute of Oncology · ITInserm · FRMayo Clinic in Arizona · USNational Cancer Institute · USRoyal Marsden Hospital · GBUniversity Children's Hospital Tübingen · DEUniversity of Basel · CHUniversity of Brescia · ITUniversity of Würzburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Our understanding of mature aggressive B cell lymphomas has evolved significantly in the last years as reflected in the 2016 update of the WHO lymphoma classification. A main topic of the 2016 European Association for Haematopathology/Society of Hematopathology lymphoma workshop in Basel therefore was the clinicopathological spectrum of mature aggressive B cell lymphomas with the exception of conventional diffuse large B cell lymphoma. In this review, we summarize two sessions dedicated to "high-grade B cell lymphomas, with MYC and BCL2 and/or BCL6 rearrangements (so-called double/triple-hit lymphomas)" and "high-grade B cell lymphomas, NOS" as defined in the 2016 update of the WHO lymphoma classification, Burkitt lymphoma and related neoplasms, and terminally differentiated aggressive B cell lymphomas. One focus was on cases of Burkitt lymphoma with unusual clinical features such as spontaneous regression or association with immunosuppression, and the new provisional category of Burkitt-like lymphoma with 11q aberration. The large numbers of cases submitted for the new high-grade categories with or without genetic "double/triple hit" demonstrated the broad clinical and pathological spectrum of this group and gave ample opportunity for discussion. In this review, current definitions and our understanding of the main high-grade categories, potential problem areas, and suggestions for the immunophenotypic and genetic work-up of these neoplasms are discussed and illustrated by many interesting and challenging cases submitted to the workshop.

Indexed as

HumansLymphoma, B-CellB cell lymphomasClinicopathologic spectrumNeoplasms

Identifiers

PMID28844114
OpenAlexW2746637654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.